High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas

被引:71
作者
Cabrera, T
Collado, A
Fernandez, MA
Ferron, A
Sancho, J
Ruiz-Cabello, F
Garrido, F
机构
[1] Univ Granada, Hosp Virgen Nieves, Dpt Anal Clin, E-18014 Granada, Spain
[2] Univ Granada, Hosp Virgen Nieves, Lab Unidad Invest, E-18014 Granada, Spain
[3] CSIC, Inst Parasitol & Biomed, Granada, Spain
来源
TISSUE ANTIGENS | 1998年 / 52卷 / 02期
关键词
alleles; class I; colon; HLA; tumor;
D O I
10.1111/j.1399-0039.1998.tb02274.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We analyzed the expression of HLA class I antigens in 78 tumor tissue samples obtained from patients diagnosed as having colorectal carcinomas. A broad panel of mAbs defining HLA monomorphic, locus-specific and allele-specific determinants was used. In addition, an antibody defining HLA-C locus-specific determinant (L31) was also tested. Previous reports on these tumors indicated HLA class I losses of 30 to 40%,. At least 73% of the patients in the present study had a detectable HLA Class I alteration, These altered HLA phenotypes were classified as total HLA loss (18%) (phenotype I); HLA-A locus-specific loss (9%) (phenotype IIIa); HLA-B locus-specific loss (8%) (phenotype mb); HLA-A and B locus losses (2%) and HLA allelic losses (36%) (phenotype IV). We found no HLA-C locus losses. Autologous peripheral blood lymphocyte HLA class I typing was always necessary to define phenotype IV, We also studied the CD3 zeta chain in tumor tissues to correlate possible changes in the CD3 signal transduction pathway with HLA alterations. The CD3 ratio was frequently altered, but this alteration could not be correlated with tumor HLA phenotypes, The high frequency of HLA class I losses in colorectal carcinomas suggests that this finding is a widespread phenomenon and may be required to escape T-cell recognition. It remains to be determined whether HLA expression is "normal" in the rest of the 27% of our patients.
引用
收藏
页码:114 / 123
页数:10
相关论文
共 29 条
  • [11] HISTOCOMPATIBILITY ANTIGENS IN PRIMARY AND METASTATIC SQUAMOUS-CELL CARCINOMA OF THE LARYNX
    ESTEBAN, F
    CONCHA, A
    HUELIN, C
    PEREZAYALA, M
    PEDRINACI, S
    RUIZCABELLO, F
    GARRIDO, F
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (03) : 436 - 442
  • [12] LOSS OF HLA CLASS-I ANTIGENS BY MELANOMA-CELLS - MOLECULAR MECHANISMS, FUNCTIONAL-SIGNIFICANCE AND CLINICAL RELEVANCE
    FERRONE, S
    MARINCOLA, FM
    [J]. IMMUNOLOGY TODAY, 1995, 16 (10): : 487 - 494
  • [13] FINKE JH, 1993, CANCER RES, V53, P5613
  • [14] NATURAL-HISTORY OF HLA EXPRESSION DURING TUMOR-DEVELOPMENT
    GARRIDO, F
    CABRERA, T
    CONCHA, A
    GLEW, S
    RUIZCABELLO, F
    STERN, PL
    [J]. IMMUNOLOGY TODAY, 1993, 14 (10): : 491 - 499
  • [15] Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
    Garrido, F
    RuizCabello, F
    Cabrera, T
    PerezVillar, JJ
    LopezBotet, M
    DugganKeen, M
    Stern, PL
    [J]. IMMUNOLOGY TODAY, 1997, 18 (02): : 89 - 95
  • [16] Garrido F, 1997, HLA GENETIC DIVERSIT, V1, P445
  • [17] GHOSH P, 1994, CANCER RES, V54, P2969
  • [18] GUTIERREZ J, 1987, EXP CLIN IMMUNOGENET, V4, P144
  • [19] FREQUENCY OF DOWN-REGULATION OF INDIVIDUAL HLA-A AND HLA-B ALLELES IN CERVICAL CARCINOMAS IN RELATION TO TAP-1 EXPRESSION
    KEATING, PJ
    CROMME, FV
    DUGGANKEEN, M
    SNIJDERS, PJF
    WALBOOMERS, JMM
    HUNTER, RD
    DYER, PA
    STERN, PL
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 405 - 411
  • [20] LOPEZNEVOT MA, 1986, IMMUNOLOGIA, V5, P51